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Abstract
Recent epidemiological studies have found that women infected with both herpes simplex virus type 2 (HSV-2) and human papillo-
mavirus (HPV) type 16 or HPV-18 are at greater risk of developing cervical carcinoma compared to women infected with only one virus.
However, it remains unclear if HSV-2 is a cofactor for cervical cancer or if HPV and HSV-2 interact in any way. We have studied the effect
of HSV-2 infection on HPV-11 gene expression in an in vitro double-infection assay. HPV transcripts were down-regulated in response to
HSV-2 infection. Two HSV-2 vhs mutants failed to reduce HPV-16 E1ˆE4 transcripts. We also studied the effect of HSV-2 infection on
preexisting experimental papillomas in a vaginal epithelial xenograft model. Doubly infected grafts demonstrated papillomatous transfor-
mation and the classical cytopathic effect from HSV-2 infection. HPV and HSV DNA signals were mutually exclusive. These studies may
have therapeutic applications for HPV infections and related neoplasms.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Infection with a high-risk type human papillomavirus
(HPV) constitutes the major risk factor for developing cer-
vical cancer (zur Hausen, 1994). HPV DNA has been found
in more than 90% of cervical cancers, and HPV-16 repre-
sents about 50% of the viral types identified (Bosch et al.,
1995). In addition to the presence of HPV DNA in cervical
neoplasias, active transcription of HPV DNA within dys-
plastic cervical lesions further establishes a strong molecu-
lar association of HPV with cervical neoplasia (for review
see Stoler, 2000). The expression of early genes E6 and E7
predominates in high-grade CIN and invasive cancers, and
E6 and E7 are also actively transcribed in cervical carci-
noma cell lines containing HPV-16 or HPV-18 (Stoler,
2000). Experimental studies on the viral oncoproteins E6
and E7 and their interactions with host cellular proteins
provide a mechanistic basis for the link between HPV in-
fection and cervical cancer. Several in vitro transformation
assays have demonstrated that high-risk types of HPV E6
and E7 can immortalize primary human foreskin or cervical
keratinocytes (McDougall, 1994). However, the E6 and E7
can transform primary cells only in the presence of an active
oncogene (Storey et al., 1995), and continued expression of
E6 and E7 is required to maintain the transformed pheno-
type (DiPaolo et al., 1993). The E6 proteins of the high-risk
types inactivate the tumor suppressor protein p53 by induc-
ing its degradation through the ubiquitin-mediated proteol-
ysis pathway (Scheffner, 1998). The E7 proteins of high-
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risk HPV bind to the tumor suppressor retinoblastoma
protein (pRb). The binding of HPV E7 to pRb destabi-
lizes pRb and results in the release of E2F (Berezutskaya
and Bagchi, 1997), which is capable of activating tran-
scription of a variety of host genes, many of which are
involved in DNA synthesis and cell-cycle progression
(zur Hausen, 2000). The activity of these oncoproteins
results in genomic instability, and this may further con-
tribute to the deregulation of HPV gene expression dur-
ing carcinogenic progression. Cells with a growth advan-
tage may be selected and give rise to clonal expansion
and tumorigenic progression, which will ultimately result
in full malignant transformation.
Although the role of high-risk HPV in cervical cancer
has been well established, it is clear that HPV is not suffi-
cient for full malignant transformation. Patients infected
with high-risk HPV do not necessarily develop cervical
cancer, indicating that other risk factors are involved. In-
vestigations in the 1970s and 1980s tried to establish herpes
simplex virus type 2 (HSV-2) as a sole etiologic agent of
cervical cancer but resulted in failure to identify a persistent
viral oncogene. Two distinct and separate transforming re-
gions (mtrII and mtrIII) have been identified within the
HSV-2 genome (Jones, 1995). Using a focus formation
assay and colony formation in a soft agar assay, mtrII was
shown to transform established rodent cells (Galloway and
McDougall, 1981). The minimal transforming fragment is
within a 737-bp fragment on the left end of mtrII (Galloway
et al., 1984). Primary hamster cells transformed by mtrIII
formed foci in monolayer cultures and transformed lines
were tumorigenic in newborn hamsters (Jariwalla et al.,
1980). HSV-2-transforming DNA sequences were not con-
sistently retained in these transformed cells, indicating that
HSV-2 may be necessary for the initiation of transformation
but not required for the maintenance of the transformed
phenotype (Galloway and McDougall, 1983). Gene prod-
ucts encoded by minimal transforming fragments were not
present or have not been identified. The existing data favor
a “hit-and-run” hypothesis for HSV-2 transformation (Gal-
loway and McDougall, 1983).
HSV-2 infection has also been proposed as a cofactor in
the development of cervical cancer (zur Hausen et al.,
1984). HSV-2 DNA has been found in 10–30% of genital
tumors (Di Luca et al., 1987). An epidemiological study
found that women infected with both HSV-2 and HPV-16 or
-18 are at greater risk of developing cervical carcinoma
compared to women infected with only one of the viruses
(Hildesheim et al., 1991). A more recent, pooled analysis of
seven case-control studies that were conducted in different
countries indicated that HSV-2 seropositivity was associ-
ated with increased risks of invasive cervical cancer among
the HPV DNA positive women, after adjustment for poten-
tial confounders, suggesting that HSV-2 infection may act
in conjunction with HPV infection to increase the risk of
invasive cervical cancer (Smith et al., 2002). However, a
perspective study conducted by Vonka and colleagues with
a cohort of 10,000 women revealed no correlation of
HSV-2 infection and increased risk of cervical cancer
(Vonka et al., 1984a, 1984b). A recent longitudinal
nested control study with a Nordic cohort of 550,000
women and the meta-analysis of six longitudinal seroepi-
demiologic studies also showed that HSV-2 did not play
a role in the development of cervical cancer (Lehtinen et
al., 2002). Transfection of nontumorigenic HPV-16-
immortalized human keratinocytes with an HSV-2 sub-
fragment containing mtrII converted these cells to tumor-
igenic squamous carcinoma cells (DiPaolo et al., 1990).
HPV-16-immortalized human fibroblasts transfected with
mtrIII formed colonies in soft agar and benign squamous
epithelial lesions in athymic mice (Dhanwada et al.,
1992, 1993) However, a recent study showed that the
right end of the subfragment of HSV-2 BglII N, Xho2,
can induce the tumorigenic conversion of HPV-
immortalized human genital epithelial cells (DiPaolo et
al., 1998). Retention and expression of this subfragment
correlated with malignancy, suggesting that either the
sequences or the products encoded by this Xho2 subfrag-
ment are required for the initiation and maintenance of
the transformed phenotype. Thus, mechanisms other than
hit-and-run may be possible in regard to HSV-2 and HPV
interactions.
Several additional studies have demonstrated close
interactions of HPV and HSV. HSV-1-encoded transac-
tivators activated HPV-16 and HPV-18 long control re-
gion (LCR) reporter gene constructs (Gius and Laimins,
1989; McCusker and Bacchetti, 1988). HPV-16 E2 can
also activate the promoter for the HSV-2 ribonucleotide
reductase large subunit (Wymer and Aurelian, 1990).
HSV-1 infection down-regulated HPV-18 E6 transcripts
in HeLa cells (Karlen et al., 1993). HSV infection re-
sulted in amplification of integrated HPV-18 DNA in
HeLa cells, which contain 10 –50 copies of integrated
HPV-18 DNA (Schwarz et al., 1985), and in replication
of transfected HPV-18 plasmid DNA in A431 cells (Hara
et al., 1997). HSV-2 infection of HeLa 229 cells was
reported to increase the transcription of E1 and E6 genes
after 20 h (Pisani et al., 2002). We studied the effect of
HSV-2 infection on HPV gene expression in vitro in a
double-infection assay and the effect of HSV-2 infection
on preexisting papillomas in vivo. In vitro double-
infection in A431 cells and RT-PCR analyses demon-
strated that HSV-2 infection down-regulates HPV tran-
scripts as a result of the HSV-2 virion associated host
shutoff protein (vhs) function. The incoming vhs associ-
ated with HSV-2 virions was sufficient for this effect. In
vivo studies, using a vaginal epithelial xenograft model
in which preexisting papillomas were superinfected by
HSV-2, demonstrated that HPV-11 and HSV-2 signals
are mutually exclusive, suggesting that HSV-2 infection
may inhibit HPV transcription and replication in papil-
lomatous cells.
148 L. Fang et al. / Virology 314 (2003) 147–160
Results
Infectivity of HPV-11 viral stock
RT-PCR of RNA extracted from A431 cells infected
with HPV-11 at various dilutions, using nested primers for
spliced HPV-11 E1ˆE4 transcripts, showed that E1ˆE4 tran-
scripts were detectable from serial dilutions of 102 to
106. This indicates that the viral stock was infectious (Fig.
1), and the infected culture dose 50(ICD50) was 106/ml.
Down-regulation of HPV-11 E1ˆE4 transcripts by HSV-2
infection
The effect of HSV-2 infection on HPV-11 gene expres-
sion was studied using an in vitro double-infection assay.
A431 cells were infected either with HPV-11 alone (Fig.
2A) or with HPV-11 and HSV-2 (Fig. 2B). Repeated RT-
PCR analyses with nested primer sets for HPV-11 E1ˆE4
showed that HSV-2 infection down-regulates HPV-11
E1ˆE4 transcripts at various time points as early as 8 h
post-HSV-2 infection (44 h post-HPV-11 infection) as in-
dicated (Fig. 2). To test if the down-regulation of HPV-11
E1ˆE4 transcripts by HSV-2 infection is cell-type-specific,
we then examined the effect of HSV-2 infection on HPV-11
gene transcripts using the same in vitro double-infection
assay in human keratinocytes immortalized by the catalytic
subunit of human telomerase (N-Tert) (Dickson et al.,
2000). The down-regulation of HPV-11 E1ˆE4 was also
observed in N-Tert cells (Fig. 3). In this experiment, down-
regulation of E1ˆE4 was observed after 12 h of HSV-2
infection (48 h post-HPV-11 infection). Nested primers for
-actin were included. Production of -actin cDNA was
measured as a quality control for RNA samples. The level of
-actin transcript appeared unchanged but decreases in this
transcript might not be detected here because this is an
abundant message and any remaining transcripts would still
score positive in this nonquantitative assay.
Down-regulation of HPV-11 E7 transcripts by HSV-2
To test if the HPV-11 E1ˆE4 transcripts were exclusively
targeted by HSV-2 infections and to further quantitate the
shutdown of HPV transcripts by HSV-2 infection, HPV-11
E7 transcripts were examined in the in vitro double-infec-
tion assay. Analysis by real-time RT-PCR using primers
and probe specific for HPV-11 E7 showed that E7 tran-
scripts were also reduced following HSV-2 infection as
early as 4 h postinfection (Fig. 4).
Down-regulation of HPV-16 E6 transcripts by the HSV-2
vhs function
To examine if viral oncogene transcripts from high-risk
types of HPV were also down-regulated by HSV-2 infec-
tion, HPV-16 E6 transcripts in HSV-2-infected CaSki cells
were examined. Because the down-regulation of HPV-11
transcripts was neither cell-type-specific nor specific for a
particular transcript, and because HSV-2 vhs is known to
mediate mRNA degradation in a sequence nonspecific man-
ner, we suspected that HSV-2 vhs may have played a role in
the down-regulation of HPV transcripts. CaSki cells in-
fected with wild-type HSV-2 were therefore also compared
with cells infected with the HSV-2 vhs mutant, 333-vhsB (a
generous gift from Dr. J. Smiley at University of Alberta,
Edmonton, Alberta, Canada). Total RNA samples extracted
from CaSki cells infected with either the wild-type HSV-2
or the vhs mutant were subjected to RT-PCR analysis using
nested primers specific to transcripts containing HPV-16 E6
(Sotlar et al., 1998). Results showed that different spliced
Fig. 1. Detection of HPV-11 E1ˆE4 transcription in infected A431 cells.
RT-PCR analysis using nested primers for HPV-11 E1ˆE4. Lane 1: high–
low molecular marker. Lane 2: H2O control. Lanes 3 and 4: uninfected
controls. Lanes 5 and 6: 102 dilution of viral stock. Lanes 7 and 8: 103
dilution of viral stock. Lanes 9 and 10: 104 dilution of viral stock. Lanes
11 and 12: 105 dilution of viral stock. Lanes 13 and 14: 106 dilution of
viral stock. The ICD50 was 106/ml.
Fig. 2. Down-regulation of HPV-11 E1ˆE4 transcripts by HSV-2 infection
in A431 cells. RT-PCR analysis using nested primers for HPV-11 E1ˆE4
and -actin. HPV-infected cells were infected with wild-type 333 HSV-2
at an m.o.i. of 10 PFU/cell in 0.5 ml medium 36 h post-HPV infection.
Expected size for the E1ˆE4 amplicon was 294 bp and for -actin was 429
bp as indicated by arrows. (A) A431 cells infected with HPV-11 alone. (B)
A431 cells infected with HPV-11 and HSV-2 at 36 h post-HPV-11 infec-
tion. RNA samples were harvested at various time points as indicated.
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forms of HPV-16 E6 transcripts, E6* I and E6 *II, are
dramatically down-regulated in wild-type HSV-2-infected
cells as early as 4 h postinfection and remained reduced up
to 48 h post-HSV-2 infection (Fig. 5A). In contrast, CaSki
cells infected with the HSV-2 vhs mutant failed to shut
down these transcripts under the same conditions, suggest-
ing that the observed shutdown of HPV transcripts was a
result of HSV-2 vhs function (Fig. 5B).
Down-regulation of HPV-16 E1ˆE4 transcripts by HSV-2
vhs function
To further quantitate the down-regulation of HPV-16
transcripts in HSV-2 infected CaSki cells and to confirm the
vhs-mediated shutdown, two different vhs mutants were
used followed by quantitative RT-PCR analyses, with prim-
ers and probes for HPV-16 E1ˆE4. The results indicated that
HPV-16 E1ˆE4 transcripts were also reduced as a result of
HSV-2 infection as early as 4 h postinfection. On the other
hand, cells infected with the two different HSV-2 vhs mu-
tants, 333-vhsB and 333-41d (a generous gift from Dr. D.
Leib, Washington University School of Medicine, St. Louis,
MO), failed to shut down HPV-16 E1ˆE4 transcripts
(Fig. 6).
De novo protein synthesis is not required for the HSV-2
vhs mediated shutdown of HPV transcripts
To investigate whether de novo protein synthesis is re-
quired for the HSV-2 vhs mediated shutdown of HPV tran-
scripts, CaSki cells were infected with HSV-2 at a multi-
plicity of infection (m.o.i.) of 10 plaque forming units
(PFU)/cell in the presence or absence of 50 g/ml cyclo-
heximide and compared with uninfected cells in the pres-
ence or absence of cycloheximide. Labeling experiments to
measure incorporation of 3H-labeled amino acids indicated
that at 50 g/ml of cycloheximide the inhibition of protein
synthesis was highly effective (data not shown). Using the
same HPV-16 E1ˆE4 primers as in the real-time PCR, the
80-bp amplicon expected was shown as a single band.
Contamination of the RNA preparation with HPV genomic
DNA might have led to an amplified product of 2558 bp.
This was not observed. The RT-PCR results showed that the
presence of cycloheximide did not change the level of HPV
E1ˆE4 transcripts in uninfected cells over a 12-h time
course (Fig. 7A), and the down-regulation of HPV E1ˆE4
transcripts consequent to HSV-2 infection was still ob-
served when de novo protein synthesis was inhibited by
cycloheximide (Fig. 7B). This implies that the shutdown of
HPV transcripts under these conditions was mainly due to
the early shutdown mediated by HSV-2 virion associated
vhs protein.
Optimized transformation of human vaginal xenografts by
HPV infection
Previously, we published HPV-11-specific papilloma-
tous transformation of human vaginal epithelial xenografts
by HPV-11 (Howett et al., 2000). To optimize the transfor-
mation rate of human vaginal xenografts by HPV-11 infec-
tion, three different conditions were tested. Human vaginal
xenografts were infected with HPV-11 by preincubation of
the tissue with the virus before grafting, or grafted directly
and then infected at 1 or 2 weeks postgrafting by injecting
the HPV-11 virus stock into the lumen of the grafted vaginal
tubes. The results showed that preincubation of the vaginal
epithelial tissue with HPV-11 before grafting or infection of
the vaginal grafts at 1 week postgrafting resulted in a higher
papillomatous transformation rate than was observed in
xenografts infected at 2 weeks postgrafting (Table 1).
Inhibition of HPV-11 activity by HSV-2 infection in the
vaginal xenograft model
The human vaginal xenograft model was adapted for the
study of HPV and HSV-2 interaction in vivo. Human vag-
inal grafts infected with HPV-11 at 1–2 weeks after xeno-
transplantation were known to be transformed by 10–13
weeks; such grafts were then infected with HSV-2. Har-
vested grafts infected with HPV-11, alone, demonstrated
areas of papillomatous transformation with koilocytes char-
Fig. 3. Down-regulation of HPV-11 E1ˆE4 transcripts by HSV-2 infection
in N-Tert cells. In vitro double-infection assay using human keratinocytes
immortalized by the catalytic subunit of human telomerase (N-Tert). RT-
PCR analysis using nested primers for HPV-11 E1ˆE4 and -actin. (A)
N-Tert cells infected with HPV-11 alone. RT-PCR products of HPV-11
E1ˆE4 transcripts are detected from 36 h post-HPV infection. (B) N-Tert
cells infected with HPV-11 and with HSV-2 at 36 h post-HPV-11 infection.
RNA samples were harvested at various time points as indicated.
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acteristic of HPV infection as previously reported (Howett
et al., 2000). Double-infected grafts demonstrated areas of
the HSV-2 cytopathic effect (Š ) by histology in addition to
areas of papillomatous transformation (3) (Figs. 8A1 and
B1). In situ hybridization using biotin-labeled HPV-11 and
HSV-2 DNA probes on adjacently cut tissue sections dem-
onstrated that papillomatous transformed cells are HPV-11-
positive, while HSV-2-positive cells were located at the
surface and edges of the papillomatous-transformed epithe-
lial areas. The HPV-11 (Fig. 8A2 and B2) and HSV-2 (Figs.
8A3 and B3) -positive signals were mutually exclusive in
grafts infected with HPV-11 and wild-type HSV-2. We have
observed this mutually exclusive pattern of HPV and HSV
DNA signals in 10 different doubly infected vaginal xeno-
grafts, suggesting that HSV-2 infection may also inhibit
HPV activity in HPV-11 transformed tissues.
Discussion
The direct role of HSV-2 in the development of cervical
cancer was extensively studied in the 1980s. However, the
link between cervical cancer and HSV is not conclusive
from early virological and epidemiological studies, suggest-
ing that HSV-2 may not be directly associated with cervical
cancer causality. The possibility remains that HSV-2 could
function as a possible cofactor in the development of cer-
vical cancer. Several studies have demonstrated close inter-
actions of HPV and HSV (Dhanwada et al., 1992, 1993;
DiPaolo et al., 1990, 1998; Gius and Laimins, 1989; Hara et
al., 1997; Karlen et al., 1993; McCusker and Bacchetti,
1988; Pisani et al., 2002; Wymer and Aurelian, 1990).
However, it remains unclear whether and how HSV-2
would function as a cofactor in the development of cervical
cancer and whether HPV and HSV-2 interact in any way
during the carcinogenic process.
Since infectious HPV-11 virus, which can be generated
using the athymic mouse model, produces low-grade dys-
plasias of cervix, vagina, and foreskin epithelium, we took
advantage of this model to study the interaction of HPV-11
and HSV-2. The effect of HSV-2 infection on HPV-11 gene
expression was examined in an in vitro double-infection
assay. Unlike several other in vitro studies, where the effect
of a particular HSV gene product on HPV gene expression
was studied using an expression plasmid and HPV LCR-
driven reporter gene constructs in the absence of the whole
viral genomes, our double-infection assays allow the study
of HPV and HSV interaction in cell lines and tissues which
can be infected by both viruses. The presence of the whole
genomes of both viruses may more closely mimic a natural
infection. Infection of 5  105 cells with a 102 dilution of
HPV stock in 2 ml of medium corresponds to an m.o.i. of at
least 0.04 to 0.4 ICD50/cell. Under these conditions,
HPV-11 E1ˆE4 transcripts can be detected by nested RT-
PCR beginning at 36 h postinfection. Total cellular RNAs
were then harvested at different time points within 48 h post
Fig. 4. Down-regulation of HPV-11 E7 transcripts by HSV-2 infection in A431 cells. In vitro double-infection assay using A431 cells established from human
epidermoid carcinoma. Total RNA was subjected to the real-time PCR analysis for HPV-11 E7. The amount of HPV-11 E7 in cells infected with HPV-11
and HSV-2 relative to the amount of HPV-11 E7 in control cells infected with HPV-11 alone was plotted against time postinfection. HPV-11 E7 transcripts
were dramatically down-regulated by wild-type HSV-2 infection.
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HSV-2 infection. These time points are early enough to
observe the effect of the HSV-2 infection on HPV tran-
scripts before the cells undergo complete lysis as a result of
HSV-2-induced cytopathic effects. The time for HSV-2
inoculation is also late enough to allow HPV transcripts to
accumulate to a detectable level so that any effect of HSV-2
on HPV transcripts will be easily detected.
Repeated RT-PCR analyses in A431 cells with nested
primer sets for HPV-11 E1ˆE4 showed that HSV-2 infec-
tion down-regulates HPV11 E1ˆE4 transcripts as early as
8 h postinfection. This down-regulation was not cell-type-
specific or specific for a particular transcript. We subse-
quently examined HPV-11 E7 transcripts in response to
HSV-2 infection by real-time RT-PCR analysis. The
amount of HPV transcripts in total RNA isolated from
HPV-11 and HSV-2 wild-type virus-infected cells, relative
to that from cells infected with HPV-11 alone, was plotted.
We suspected that HSV-2 vhs protein may be involved,
since HSV-2 vhs is known to shut off host protein synthesis by
disruption of preexisting polyribosomes and accelerated deg-
radation of host mRNA in a sequence-nonspecific manner and
that binding of vhs by VP16, another HSV-2 protein, is re-
quired to allow accumulation of viral transcripts at a later stage
of infection (Smiley et al., 2001). We found that HSV-2 vhs
mutants failed to down-regulate HPV-16 E1ˆE4 and E6 tran-
scripts in CaSki cells. Similar results were found by real-time
RT-PCR for HPV-16 E1ˆE4 transcripts in CaSki cells using
two independently derived HSV-2 vhs mutants. However, this
conclusion does not eliminate the involvement of other HSV-2
proteins in vivo. The level of HPV transcripts was not restored
to the level at zero time point of infection, especially at later
time points, suggesting that other HSV-2 proteins may also be
involved. It has been suggested that the delayed secondary
shutoff requires de novo protein synthesis and is mediated by
the immediate-early HSV-2 protein, ICP27. ICP27 causes host
shutoff through regulation of small nuclear ribonucleoprotein
distribution and inhibition of mRNA splicing (Phelan and
Clements, 1998). The immediate early protein ICP22, which
acts through an alteration in the phosphorylation state of RNA
polymerase II to specifically repress cellular gene transcription,
also aids in host shutoff (Phelan and Clements, 1998). The
results of our studies are not in agreement with observations
from several other studies where several HSV transactivators
were found to enhance HPV gene expression in in vitro sys-
tems when studied in the absence of the whole viral genomes
(Gius and Laimins, 1989; McCusker and Bacchetti, 1988).
This suggests that HPV and HSV interact differently in the
context of intact viral genomes during a natural infection com-
pared to genes in isolation. Our results are similar to the
observation made in HSV-1-infected HeLa cells where hyper-
sensitivity of HPV-18 E6 transcripts to the HSV-1 vhs function
was observed (Karlen et al., 1993). Apparently, the vhs func-
tion of the different types of HSV is conserved and the effect
of HSV on HPV of both high-risk types and low-risk types is
similar.
The presence of cycloheximide did not affect the shut-
down of HPV transcripts, suggesting that our observations
are mainly due to the early shutdown mediated by the
HSV-2 virion-derived vhs. Using this semiquantitative as-
say, HPV transcript levels appeared to be slightly higher in
HSV-2-infected cells in the presence of cycloheximide
compared to those cells in the absence of cycloheximide;
this may be due to the stabilization effect on polyribosomes
by cycloheximide (Arbuzov, 1978). This result also implies
that in the situation of an abortive HSV infection or in the
presence of defective particles, the vhs-mediated shutdown
of HPV is equally likely. If the infected cells are not killed
by HSV infection, the effect of vhs-mediated shutdown on
cells and the repertoire of HPV genes expressed may affect
the course of HPV infection and contribute to the carcino-
genic process.
The shutdown of HPV viral oncogene transcripts by
HSV-2 vhs function raises the possibility of using regulated
expression of HSV vhs as a therapeutic application for
cervical neoplasms. Previous reports have shown that ex-
pression of vhs reduced gene expression from a cotrans-
fected reporter plasmid (Pak et al., 1995). Vhs expression
has also been shown to inhibit human immunodeficiency
virus replication in transfected cells (Hamouda et al., 1997).
Therefore, it may be possible to use regulated expression of
vhs targeted to cervical cancer cells as a therapeutic agent
Fig. 5. Down-regulation of HPV-16 E6 transcripts by HSV-2 vhs function.
RT-PCR analysis for HPV-16 E6. The expected size for various forms of
HPV-16 E6 transcripts (Table 2) are 395 bp (E6/E7 unspliced), 213 bp
(E6*I), and 95 bp (E6*II). (A) CaSki cells infected with wild-type HSV-2.
(B) CaSki cells infected with HSV-2 vhs mutant. RNA was harvested at
various times postinfection as indicated.
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for cervical papillomas or cervical cancer. However, the
effects of vhs on cellular functions need to be systematically
studied before it can be developed into a therapeutic agent.
No study has ever examined the interaction of HPV and
HSV in vivo in the context of natural human vaginal tissue.
Previous experiments in our laboratory have demonstrated
Fig. 6. Down-regulation of HPV-16 E1ˆE4 transcripts by HSV-2 vhs function. Real-time PCR analysis for HPV-16 E1ˆE4. The amount of HPV-16 E1ˆE4
in infected cells relative to the amount of HPV-16 E1ˆE4 in mock-infected cells was plotted against time postinfection. Bars represent the relative amount
of HPV-16 E1ˆE4 transcripts from cells infected with wild-type HSV-2 or two different HSV-2 vhs mutants at various times postinfection, as indicated. (A)
Relative amount of HPV-16 E1ˆE4 transcripts at various time points in cells infected with wild type HSV-2 or HSV-2 333-vhsB mutant. (B) Relative amount
of HPV-16 E1ˆE4 transcripts at various time points in cells infected with wild-type HSV-2 or 333-41d mutant.
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that the vaginal epithelium can serve as a target for produc-
tive infection and neoplastic transformation by HPV-11
(Howett et al., 2000). Results showed that double-infected
grafts, by histology, demonstrated areas of the HSV-2 cy-
topathic effect in addition to areas of papillomatous trans-
formation. In situ hybridization using HPV-11 and HSV-2
DNA probes on adjacently cut tissue sections demonstrated
that papillomatous transformed cells are HPV-11-positive,
while HSV-2-positive cells were located at the surface and
edges of the papillomatous transformed epithelial areas or at
basal layers of the epithelia. HSV-2 and HPV-positive sig-
nals were mutually exclusive, indicating that HSV-2 infec-
tion, acute, recurrent, or persistent, may inhibit HPV mac-
romolecule synthesis in preexisting papillomas. Although it
is difficult to show that HSV-2 virions are exposed to the
same cells that are infected by HPV, we have observed this
mutually exclusive pattern of HPV and HSV DNA signals
in 10 different doubly infected vaginal xenografts. The
inhibition of HPV activity was also observed in layers
above HPV-11-positive cells in terminally differentiated
layers of the epithelia, which would normally stain positive
for HPV-11 all the way to the cornified layers of the epi-
thelia (Fig. 8B2). Areas which are negative for HPV-11
stained positive for HSV-2 (Fig. 8B3). These results suggest
that HSV-2 infection may inhibit HPV activities. The data
are in agreement with our in vitro data for the down-
regulation of HPV transcripts by HSV-2 infection, suggest-
ing that the effect of HSV on HPV gene expression ob-
served in vitro could happen in vivo as well. We do not
know, however, that the effects observed in vivo are solely
mediated by vhs.
The most direct interpretation of our in vitro and in vivo
data suggests that HSV-2 infection inhibits HPV activities
and therefore may result in ablation of papillomas. Epide-
miological studies found conflicting results for the associa-
tion of HSV-2 and increased risk of cervical cancer. The
recent longitudinal nested control study with a Nordic co-
hort of 550,000 women, and the meta-analysis of six lon-
gitudinal seroepidemiologic studies on the association of
HSV-2 with cervical neoplasia showed that HSV-2 did not
play a role in the development of cervical cancer (Lehtinen
et al., 2002). In fact, these studies revealed that among
HPV-seropositive women, HSV-2 seropositivity was asso-
ciated with a slightly decreased risk of developing cervical
cancer. The association of HSV-2 infection with cervical
cancer found in several cross-sectional case control studies
may be biased, since the cross-sectional design itself cannot
exclude the possibility that cervical neoplasia predisposes to
HSV-2 infection.
Several alternative possibilities for the outcome of
HSV-2 infection-mediated down-regulation of HPV can be
proposed. HSV-2 infection may initially cause the cyto-
pathic effect and tissue destruction, which may result in
partial ablation of the preexisting papillomas. Tissue de-
struction followed by immune clearance of HSV-2, how-
ever, may lead to stimulation of papilloma growth during
repair of injury and therefore promote carcinogenic progres-
sion. In addition, defective particles may not kill infected
cells, and the effect of vhs mediated shutdown on these
surviving cells and the repertoire of HPV genes expressed
may alter HPV infection and promote tumor growth through
changes in HPV integration, amplification, or mutagenic
events. It is unknown at this point if alterations in HPV gene
expression by HSV-2 contribute to the carcinogenic process
or if the down-regulation of HPV macromolecule synthesis
results in in vivo ablation of the papilloma. Further studies
using various HSV-2 mutants in this xenograft model, such
as HSV-2 vhs or HSV-2 replication defective mutants, may
Fig. 7. De novo protein synthesis is not required for the HSV-2 vhs
mediated shutdown of HPV transcripts. RT-PCR analysis for HPV-16
E1ˆE4Eˆ 4 using the same primers as in the real-time PCR. (A) Uninfected
CaSki cells. Lanes 1–4: uninfected CaSki cells without cycloheximide
harvested at 0, 4, 8, and 12 h. Lanes 5–8: uninfected CaSki cells with
cycloheximide harvested at 0, 4, 8, and 12 h. Lane 9: 100-bp molecular
marker. (B) HSV-2-infected CaSki cells. Lanes 1–4: HSV-2-infected
CaSki cells without cycloheximide harvested at 0, 4, 8, and 12 h postin-
fection. Lanes 5–8: HSV-2-infected CaSki cells with cycloheximide har-
vested at 0, 4, 8, and 12 h. Lane 9: 100-bp molecular marker.
Table 1
Optimization of human vaginal xenograft athymic mouse model





A: Preincubation of human vaginal epithelia tissue with virus before
grafting; B: virus inoculation at one week postgrafting; C: virus inoculation
at 2 weeks postgrafting.
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allow longer incubation times for HSV-2-mediated carcino-
genic conversion of HPV-induced papillomas. In addition,
the effect of the vhs on preexisting papillomas may be
studied by transduction of the vhs gene to preexisting pap-
illomas. These studies are currently in progress. The poten-
tial limitation of this animal model is that HPV-11-induced
transformations are not uniform and HSV-2 infections on
preexisting papillomas are opportunistic as well. Therefore,
large numbers of human xenografts in animals may be
needed to make definitive conclusions.
The in vivo and in vitro results also suggest the possi-
bility of using HSV-2 for the treatment of cervical carci-
noma. The idea of using viruses as oncolytic agents has
been suggested in the past (Kenney and Pagano, 1994). The
fact that cervical epithelial cells are the natural targets of
HSV-2, and that HSV-2 is highly cytolytic, makes it a good
candidate as an oncolytic agent for cervical cancer. The
toxicity associated with HSV-2 infection would clearly pre-
vent the use of wild-type HSV-2 for treatment of human
cancer. However, with advanced genetic manipulation, it
may be possible to develop HSV-2 mutants which will
maximize the killing of tumor cells and minimize the tox-
icity to normal cells. Replication-competent HSV has been
demonstrated to be an effective oncolytic agent for several
malignant tumors. These HSV mutants have been engi-
neered to reduce virulence in normal tissues while main-
taining oncolytic ability. Deletion mutants of HSV-1, such
as thymidine kinase (TK) deletion and ribonucleotide re-
ductase (RR) deletion, have been made for the treatment of
brain tumors (Andreansky et al., 1997; Kramm et al., 1997).
Inhibition of oral cancer tumor growth by HSV-1 in a
mouse model has been shown, and the inhibition was de-
pendent on the ability of the virus to replicate in the tumor
(Lou et al., 2002). The HSV-1 ICP34.5 null mutant has been
shown to effectively treat experimental human melanoma in
mice, and virus replication was severely attenuated in nor-
mal tissue through unclear mechanisms (Randazzo et al.,
1997). HSV-1 G207, which was constructed with deletions
in both the ICP34.5 gene and a lacZ gene inserted into the
ICP6 gene, demonstrated efficient and selective cytotoxicity
and tumor growth inhibition of human head and neck squa-
mous cell carcinoma (Carew et al., 1999). However, mu-
tants that work for brain tumors or oral cancer may not work
for cervical cancer. Other mutants may have to be devel-
oped to target cervical cancer cells specifically. One way to
regulate the replication of HSV-2 would be to replace the
promoter of an essential gene with a promoter that is selec-
tively active in cervical cancer cells.
Materials and methods
Generation of experimental HPV-11-infected papillomas
Experimental papillomas and HPV-11 virus stocks were
generated as previously described (Kreider et al., 1987).
Briefly, human foreskins were obtained from neonatal cir-
cumcisions and placed into minimum essential medium
(MEM) containing gentamycin (0.4 mg/ml), penicillin and
streptomycin (0.08 mg/ml each), fungizone (2.5 g/ml),
sodium bicarbonate (0.05%), and HEPES (10 mM). Human
foreskin tissue was then cut split-thickness into pieces mea-
suring approximately 2  2  0.5 mm. Tissues were incu-
bated with HPV-11 virus inoculum for 1 h at 37°C. The
original cell-free extract of HPV-11 used in the xenograft
system was obtained from pooled patient condylomata
acuminata (Kreider et al., 1985). Infected tissue chips were
then transplanted under the mouse renal capsule. The grafts
were allowed to grow for 3–5 months. Infected foreskin
grafts transformed by HPV-11 often produce condyloma-
tous cysts of 1–2 cm in diameter. Keratin cores were re-
moved from experimentally developed condylomatous cysts
and kept at 70°C; these cores were used for preparation of
additional virus stocks.
Preparation of HPV-11 viral stock
HPV-11 viral stock was prepared as previously described
(Kreider et al., 1987). Briefly, keratin cores removed from
experimentally developed condylomatous cysts and kept at
70°C were thawed and weighed. Keratin was then ground
with sterile sea sand and 2 volumes (w/v) of PBS with a
mortar and pestle. The resultant paste was centrifuged at
11,000 g at 4°C for 5 min. The supernatant was removed
and stored at 70°C.
Preparation of HSV-2 virus stock
HSV-2 viral stocks were prepared as described previ-
ously (Adelman et al., 1980). Briefly, confluent African
green monkey kidney cells were infected with the HSV-2
strain 333 virus stock at a low m.o.i. (0.1 PFU/cell) in a
small volume of sterile Tris-buffered saline (137 mM NaCl,
2.68 mM KCl, 25 mM Tris, pH 7.4). The virus inoculum
was replaced by fresh Dulbecco’s MEM (supplemented
with 10% fetal calf serum, 1.5 g/L NaHCO3, 100 U/ml
penicillin G, 100 mg/ml streptomycin) after 1 h of incuba-
tion at 37°C. Incubation was continued for 24–36 h until the
cells showed complete cytopathic effects. Flasks were fro-
zen and thawed and media were pooled. Cell debris was
pelleted by centrifuging for 5 min (200 g) at 4°C. The
supernatant was aliquoted and stored at 70°C.
Assay for infectivity of HPV-11 viral stock
The infectivity of HPV-11 viral stock was determined as
described previously (Ludmerer et al., 2000; Smith et al.,
1995). Briefly, the HPV-11 viral stock was serially 10-fold
diluted in Dulbecco’s medium (supplemented with 10%
FCS, 100 U/ml penicillin G, 100 mg/ml streptomycin, 1.5
g/L NaHCO3, 2.8 g/L HEPES). A431 cells established from
human epidermoid carcinoma (Giard et al., 1973) were
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seeded in six-well plates (5  105 cells/well) 1 day prior to
infection with serially diluted HPV-11 stock in 1 ml of
culture medium. An additional 2 ml of culture medium was
added after overnight incubation at 37°C, and cells were
incubated for an additional 2 days. Total cellular RNA was
extracted 72 h postinfection using a QIAshredder and
RNeasy mini kit (Qiagen, Valencia, CA). RT-PCR analysis
of the HPV-11 E1ˆE4 transcript was used to determine the
end-point dilution of virus that still initiated infectivity.
Titration of HSV-2 by plaque assay
HSV-2 viral titers were determined as described previ-
ously (Adelman et al., 1980). Briefly, the virus samples to
be titrated were serially 10-fold diluted in Dulbecco’s MEM
as described above. Confluent African green monkey kid-
ney cells (CV-1 or Vero) seeded in 60-mm tissue culture
plates were inoculated with diluted viruses and incubated at
37°C for 1 h. At the end of incubation, virus inoculum was
removed and 5 ml of methylcellulose medium was added to
each plate. The plates were incubated for 1 to 4 days and
fixed and stained with 5% formaldehyde and 0.5% crystal
violet. Plaques were counted and the virus titer was ex-
pressed in plaque-forming units.
In vitro double-infection assay
A431 cells were seeded in six-well plates (5 105/well).
On the next day, cells were infected with 102 diluted
HPV-11 viral stock in 2 ml of medium. HPV-infected cells
were then infected 36 h post-HPV infection with wild-type
333 HSV-2 or HSV-2 mutants (333-vhsB and 333-41d) at
an m.o.i. of 10 PFU/cell in 0.5 ml medium. The HSV-2
333-vhsB mutant was constructed by disruption of the
UL41 ORF in HSV-2 strain 333 DNA by insertion of an
expression cassette consisting of the Escherichia coli lacZ
gene driven from the HSV-1 ICP6 promoter into a BstX1
restriction site at codon 30. The mutation was transferred to
HSV-2 by marker rescue. The 333-d41 mutant HSV-2 has a
939-bp deletion in vhs. The HSV-2 inoculum was replaced
by medium after a 1-h incubation. Total cellular RNA was
extracted every 4 h from the point of HSV infection for 24 h
Fig. 8. Inhibition of HPV-11 activity by HSV-2 infection in the vaginal xenograft model. Human vaginal grafts infected with HPV-11 at 1–2 weeks after
xenotransplantation were then infected with HSV-2 and harvested 1 week post-HSV-2 infection. (A1 and B1) Hematoxylin and eosin staining of two different
formalin-fixed and paraffin-embedded doubly infected xenograft longitudinal sections. Grafts demonstrated areas of papillomatous transformation with
koilocytes characteristic of HPV infection (Š ) and areas of HSV-2 cytopathic effect located at the edge and surface of the graft (3). (A2 and B2) In situ
hybridization of adjacently cut sections of the same area as in A1 and B1, respectively, probed with biotin-labeled HPV-11 DNA. Areas of papillomatous
transformed cells stained dark purple are HPV-11 positive. (A3 and B3) Adjacently cut section of the same areas as in A2 and B2, respectively, probed with
biotin-labeled HSV-2 DNA probe. HSV-positive cells stained dark purple are located at the surface and edges of the papillomatous-transformed epithelial
cells and the HPV-11- and HSV-2-positive signals are mutually exclusive in the doubly infected grafts.
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using the RNeasy mini kit (Qiagen). RNA samples were
stored at 70°C.
RT-PCR analysis of HPV-11 E1ˆE4 transcripts
Total cellular RNA (200 ng) extracted from infected
A431 cells was reverse transcribed in the presence of RT
buffer, 5 mM MgCl2, 1 mM of dNTPs, 5 M 11-DO, and
A-DO primers (Table 2) and 2.5 U of reverse transcriptase
in a total volume of 20 l at 42°C for 1 h. The product was
amplified using nested primer sets (Table 2) and two 30-
cycle PCR rounds to detect the HPV-11 E1ˆE4 spliced
transcript (Ludmerer et al., 2000; Smith et al., 1995). -ac-
tin primer sets (Table 2) were included in PCR reactions to
serve as an internal control for RNA integrity. Following
cDNA synthesis primers 11-UO and A-UO were used for 30
cycles of PCR (temperature file: 94°C/30 s, 60°C/30 s,
72°C/55 s with a final extension of 72°C/10 min). A portion
(5 l of 100 l) of the PCR reaction mixture was then
utilized for a second 30 cycles of PCR primed with primers
11-UI, 11-DI, A-DI, and A-UI using the same temperature
profile. PCRs were conducted according to the manufactur-
er’s instruction (GeneAmp RNA PCR kit, Perkin–Elmer,
Branchburg, NJ). The final concentration of deoxynucle-
otide triphosphates during PCR was 0.2 mM and final con-
centrations of primers were 0.2 M in all cases. The final
expected size for the E1ˆE4 amplified product was 294 bp,
and the amplified product was for -actin was 429 bp.
RT-PCR analysis of HPV-16 E6 transcripts
Total cellular RNA (200 ng) extracted from CaSki cells
was reverse transcribed in the presence of RT buffer, 5 mM
MgCl2, 1 mM dNTPs, 0.2 M S4 primer as previously
described (Sotlar et al., 1998), and 2.5 U of reverse tran-
scriptase in a total volume of 20 l at 42°C for 1 h. The
primers are shown in Table 3. Following cDNA synthesis,
primers S4 and S3 specific for HPV-16 E6 (Table 3) were
used at 0.04 M for 30 cycles of PCR (temperature file:
94°C/30 s, 60°C/30 s, 72°C/55 s). The first cycle is preceded
by a 2-min denaturation at 94°C and the final cycle is
followed by a final extension of 72°C for 10 min. A portion
(5 l of 100 l) of the PCR reaction mixture was then
utilized for a second 15 cycles of PCR primed with nested
primers S1 and S2 (Table 2) at 0.4 M using the same
temperature profile. PCRs were conducted according to the
manufacturer’s instruction (GeneAmp RNA PCR kit from
Perkin–Elmer). The final concentration of deoxynucleotide
triphosphates during PCR was 0.2 mM. The final expected
size for various forms of HPV-16 E6 transcripts are 395 bp
(E6/E7 unspliced), 213 bp (E6*I), and 95 bp (E6*II). PCR
products (10 l) were analyzed by electrophoresis on aga-
rose gels and stained with ethidium bromide.
Real-time RT-PCR analysis of HPV-16 E1ˆE4
and HPV-11 E7 transcripts
Total cellular RNA isolated from CaSki or A431 cells
was treated with DNase (DNA-free RNA kit, Zymo Re-
search, Orange, CA) according to the manufacturer’s in-
structions. Quality control (Agilent Technologies 2100 Bio-
analyzer, Palo Alto, CA) was done on an aliquot of each
DNase-treated RNA to ensure purity and integrity of the
RNA. The RNA was then reverse transcribed using the
Thermoscript RT-PCR system with random hexamer prim-
ers according to the manufacturer’s instruction (Invitrogen
Life Technologies, Carlsbad, CA). Amplification of the
resulting cDNA was carried out in duplicate or triplicate,
using TaqMan PCR Core Reagents (Applied Biosystems,
Foster City, CA). All primers (Table 4) were synthesized at
the Macromolecular Core Facility, Penn State College of
Medicine and used at a final concentration of 900 nM. The
fluorogenic probes (Table 4) were ordered from MWG
Biotech, High Point, NC and used at a final concentration of
200 nM. Standard curves were also run in parallel for each
analysis using CaSki or HPV-11-infected A431 cell cDNA
with twofold serial dilution down to 1:256. Amplifications
were carried out in a 96-well plate in the Applied Biosys-
tems Prism 7700 Sequence Detection System (Applied Bio-
systems). For HPV-16 E1ˆE4 amplification, 1 l (50 ng) of
the CaSki cell cDNA was used in a total volume of 50
Table 3
Reverse transcriptase and polymerase chain reaction primers
for HPV-16 E6






Note. Primer pairs specific for HPV-16 E6 and their corresponding
nucleotide sequences are shown as published in Sotlar et al. (1998).
Table 2
Reverse transcriptase and polymerase chain reaction primers for HPV-11
E1ˆE4 and -actin











Note. Primer pairs, specific for HPV-11 E1ˆE4 and -actin and their
corresponding nucleotide sequences are shown as published in Ludmerer et
al. (2000) and Smith et al. (1995).
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l/well. Parallel detection of 18S cDNA for each sample
utilized reagents from a commercially available kit (TaqMan
Ribosomal RNA Control Reagents, Applied Biosystems) with
a fluorescent group, VIC, as the reporter. Alternatively, mock-
infected CaSki cDNA of various time points was used as
control. The annealing temperature was 55°C. The expected
amplicon for HPV-16 E1ˆE4 from spliced cDNA is 80 bp and
the predicted size for the amplification product from the
HPV-16 genome is 2558 bp; genomic product is never ob-
served on gels. For HPV-11 E7, 3 l (67.5 ng) of A431 cell
cDNA was amplified in a total volume of 50 l/well. A431
cDNA from samples infected with HPV-11 alone was used as
control. The annealing temperature was 60°C. The expected
amplicon for HPV-11 E7 is 110 bp.
In vivo double-infection assay
Human vaginal tissue was obtained from resected vagi-
nal wall removed during reconstructive surgeries. Speci-
mens were held at 4°C until grafting (within 24 h) in MEM
supplemented with gentamycin (0.4 mg/ml), penicillin and
streptomycin (0.08 mg/ml each), fungizone (2.5 g/ml),
sodium bicarbonate (0.05%), and HEPES (10 mM). Split-
thickness human vaginal epithelia (20  20  1 mm) were
rolled into tubes with the vaginal epithelial surface on the
inside and grafted subcutaneously to athymic mice receiv-
ing estrogen supplementation in silastic tubes (Sigma
Chemical Co., St. Louis, MO) to maintain 150–200 pg/ml
estrogen in circulation (Robinson et al., 1989). At 1–2
weeks after xenotransplantation, grafted vaginal tubes were
infected with 10 l of infectious HPV-11 virus stock by
opening the skin, exposing one end of the graft, and then
inserting a micropipette tip into the xenograft lumen. By
10–15 weeks, grafts are known (from previous experi-
ments) to be morphologically transformed and productively
infected by HPV-11 (Howett et al., 2000). Grafts were then
infected with HSV-2 at 10–15 weeks. One week following
HSV-2 infection, infected grafts were harvested by excision
and longitudinal sectioning of grafts for standard morphol-
ogy (standard formalin-fixed, paraffin embedded, hematox-
ylin and eosin stained histology sections), for virus DNA
content (in situ hybridization). (Fig. 8) as previously de-
scribed (Howett et al., 2000).
3H-labeling assay for assessment of protein synthesis
CaSki cells were seeded at 5  105 cells/plate in 60-mm
tissue culture plates the night before infection. Cells were then
infected with HSV-2 at an m.o.i of 10 PFU/cell in the presence
of 50 g/ml cycloheximide (U.S. Biological, Swampscott,
MA) or without cycloheximide as a control. After 1-h incuba-
tion at 37°C, virus inoculum was replaced by medium con-
taining 3H-labeled amino acids at 10 Ci/ml and incubated at
37°C for 4 h. Cells were then washed twice with PBS and
scraped off the plates into 1 ml of PBS. Cells were spun down
and the cell pellet was resuspended in 200 l RIPA buffer (1%
Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS in PBS).
Ten microliters of the above cell lysate was spotted onto a filter
paper and washed twice with 5% TCA, 95% ethanol and
acetone, respectively. The filters were air-dried before count-
ing in the scintillation counter in the presence of Scintisafe
Econol 1 (Fisher, Pittsburgh, PA).
In situ hybridization
A biotin label was incorporated into DNA using the
random priming method (Amersham, Cleveland, OH).
Deparaffinized, rehydrated sections of standard paraffin-
embedded tissues were digested with pepsin (4 mg/ml in 0.1
N HCl), washed in Tris–HCl, pH 7.5, dehydrated, and
covered with a hybridization cocktail containing 0.6 M
NaCl, 10 mM Tris pH 7.4, 0.5 mM EDTA, 1 mg/ml bovine
serum albumin (BSA), 0.02% polyvinylpyrrolidone (PVP)
(w/v), 0.02% Ficoll (w/v), 0.15 mg/ml yeast tRNA, 5 mM
DTT, 10% dextran sulfate (w/v), 50% formamide (v/v), and
1 ng/l labeled DNA. The probe and tissue were denatured
together by heating the slides at 100°C for 6 min. After heat
denaturation, slides were incubated in a moist chamber at
37°C for 2 h, washed three times for 10 min each in 2 
SSC (0.3 M sodium chloride and 0.03 M sodium citrate, pH
7.0), and incubated with avidin-conjugated alkaline phos-
phatase for 30 min. After washing in Tris–HCl buffer (pH
9.5) three times for 10 min, the McGady reagent was used
to develop signal color and sections were counterstained
with Nuclear Fast Red.
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